Newsletter | July 23, 2025

07.23.25 -- Imunon Talks Passionate PIs, Endpoint Selection In Frontline Ovarian Cancer Trials

SPONSOR

Slow The Burn: How To Make Risk-Resilient Vendor Choices

Discover how to spot the most common red flags when selecting a CRO and avoid costly setbacks in your clinical program. Gain expert strategies to strengthen contracts, improve vendor accountability, and protect your budget.

TRIAL MANAGEMENT

Imunon Talks Passionate PIs, Endpoint Selection In Frontline Ovarian Cancer Trials

Guest Column | A conversation with Stacy Lindborg, Ph.D., CEO, IMUNON

Stacy Lindborg, Ph.D. details the company’s successes in site selection, as well as trial design and execution, in Phase 2 and 3 trials for IMNN-001, a frontline treatment for ovarian cancer.

Completed Clinical Trials Continue To Climb

White Paper | By Drew Muscara, Citeline

Data collected in this report reflects a shift toward sustained growth, reflecting rapid advancement in therapeutic areas such as oncology, autoimmune/inflammation, and central nervous system studies.

HEOR In Action

Infographic | ISPOR—The Professional Society for Health Economics and Outcomes Research

Health Economics and Outcomes Research (HEOR) plays a vital role in guiding evidence-based decisions across the healthcare ecosystem.

How Strategic Resourcing Accelerates Biotech's Path From Preclinical To FIH

Article | TFS HealthScience

Explore how strategic resourcing, particularly through FSP models, empowers biotech sponsors to overcome common hurdles transitioning when from preclinical research to first-in-human (FIH) trials.

The Benefits Of Using Community Research In Obesity And Diabetes Trials

Article | By Miranda McLaren, PCM Trials

The obesity drug development landscape is rapidly evolving, but despite this promising trajectory, significant barriers in patient recruitment and retention persist.

Make Sense Of Unstructured Data In Neurology, Urology, and Ophthalmology

Video | Verana Health

Transform your data and, ultimately, patient outcomes across three major therapeutic areas: Neurology, Urology, and Ophthalmology.

DECENTRALIZED TRIALS

Local HCPs in DCTs: Big Benefits, Bigger Burdens?

From The Editor | By Dan Schell, chief editor, Clinical Leader

Local HCPs in DCTs provide benefits like improved patient accessibility and retention, but create significant oversight burdens for investigators and sponsors, requiring extensive documentation and training protocols to maintain compliance.

Top 10 Challenges And Solutions For Decentralized Clinical Trials

Article | DIA

Decentralized clinical trials are reshaping research, but what are the biggest roadblocks to their full potential? We delve into the top 10 challenges and the cutting-edge solutions emerging.

Remote ECG Solution Enables A Fully Decentralized ME/CFS Phase 2 Trial

Case Study | AliveCor BioPharma

Discover the transformative potential of digital health tools in addressing longstanding accessibility challenges in ME/CFS research and beyond.

CHOOSE YOUR OWN ADVENTURE

You're receiving the Wednesday edition of the Clinical Leader newsletter, focusing on Decentralized Trials and Trial Management. To make changes to your newsletter selections, update your topic preferences.

  • Clinical Sites | Patient Centricity | Patient Recruitment (Monday)
  • Clinical Trial Technology (Tuesday)
  • Decentralized Trials | Trial Management (Wednesday)
  • Outsourcing Models | Regulatory & Compliance (Thursday)
  • Clinical Data Management & Analytics | Trial Monitoring (Friday)

Learn more about our personalized newsletters here.

Connect With Clinical Leader: